Centene Corporation (CNC) announced its financial results for the third quarter ending on September 30, 2024. The healthcare company reported a solid performance, showing resilience amidst market challenges and delivering on key financial indicators. Let’s dive into the highlights from Centene’s Q3 earnings report, examining the implications for investors.
Before we dive in, we have a special offer! For a limited time, you can get 70% off Stock Target Advisor’s premium features. Claim your discount here!
Key Insights from Centene Corp’s Earnings Report:
Centene’s Q3 report revealed a diluted EPS of $1.36 and an adjusted diluted EPS of $1.62. The company reaffirmed its 2024 adjusted diluted EPS guidance floor of greater than $6.80, signaling confidence in its annual performance. The company’s premium and service revenues reached $36.9 billion, reflecting a 6% increase from the same period last year. Notably, Centene experienced substantial growth in its Marketplace and Medicare Prescription Drug Plan memberships, with increases of 22% and 49% respectively.
The health benefits ratio (HBR) rose to 89.2% in Q3, up from 87.0% last year, driven by higher acuity in Medicaid members. The company continued its share repurchase activities, buying back $1.2 billion worth of shares during Q3, with an additional $380 million repurchased in October 2024.
Positive Implications for Investors:
Centene’s diversified portfolio and strategic growth in key segments have positioned it well for the long term. The company’s commitment to capital deployment, evidenced by its share repurchase program, indicates a solid cash flow and the management’s confidence in future growth. Additionally, Centene’s successful contract renewals and expansions in key states such as California, Pennsylvania, Iowa, and Florida demonstrate strong momentum in government healthcare programs.
Moreover, Centene’s improvement in Medicare Advantage Star Ratings, with nearly 46% of its members now in plans rated 3.5 stars or higher, reflects the company’s emphasis on quality care and operational efficiencies, which could positively impact future revenue.
Is now the time to buy Centene? Access our full analysis report here, it’s free.
Negative Implications for Investors:
Despite these gains, there are some challenges investors should note. The rise in the health benefits ratio suggests that Centene is facing higher costs, which could continue to pressurize margins if not addressed. Additionally, the company reported a cash flow usage of $978 million in operations, highlighting short-term liquidity challenges influenced by delays in Medicaid rate adjustments and increased Part D receivables.
The report also noted that the company’s effective tax rate decreased to 22.9% from last year’s 38.2%, potentially reflecting complexities in managing tax implications amid operational adjustments.
Stock Target Advisor’s Analysis on Centene Corp:
According to Stock Target Advisor, Centene Corp has a target price of USD 89.75 over the next 12 months based on forecasts from 11 analysts. The stock receives a “Neutral” rating due to mixed indicators—seven positive and seven negative signals. On the positive side, Centene’s stock is underpriced compared to earnings and book value, and it shows strong cash flow metrics and superior revenue and earnings growth over five years. However, investors should be cautious about the company’s high volatility, poor risk-adjusted returns, below-median dividend yields, and low returns on equity and assets.
Conclusion:
Centene Corp’s Q3 earnings report showcases a company with strong growth in membership and service revenues and a strategic focus on capital deployment. Stock Target Advisor’s neutral stance underscores a balanced perspective—offering growth potential for investors who can navigate the inherent risks.
Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product/services forecast as indicated by major brokers covering the stock.
